文献速递眼底病与葡萄膜炎

EMERALD研究:糖尿病视网膜病变并发症新型照护模式评估

Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study.
PubMed 文献 · Ophthalmology · 2020-10-31

EMERALD研究是在英国13家医院开展的前瞻性、多中心、病例参照、横断面诊断准确性研究,评估由非医务人员解读多模态影像检测既往治疗过的DME或PDR复发的诊断准确性、可接受性和成本。新路径检测DME的敏感度为97%、特异度为31%,检测PDR的敏感度与特异度与标准照护可比,且可节省费用。

要点

  • 新路径检测DME敏感度97%、特异度31%;检测PDR敏感度83%-85%、特异度48%-54%。
  • 高危PDR使用UWF图像的敏感度87%、特异度49%,优于7视野ETDRS的80%和40%。
  • 新路径每100次DME随访可节省1390英镑,每100次PDR随访节省461至1189英镑。

核心结论

  • 新路径对检测DME和PDR具有可接受的敏感度,并可释放资源、节省费用。
  • 使用者偏好眼科医师评估,在无法实现时偏好阅片员即时反馈并保留定期眼科医师评估。

研究设计与样本

  • 前瞻性、多中心、病例参照、横断面诊断准确性研究,在英国13家医院开展。
  • 纳入既往成功治疗DME或PDR的1型或2型糖尿病成人,入组时疾病活动或非活动。
  • 新路径由培训过的非医务人员阅片多模态影像(SD-OCT、7视野ETDRS和UWF眼底图像)检测疾病复发,与眼科医师面对面检查的标准照护比较。

主要发现

  • 新路径检测DME的敏感度为97%(95%CI 92%-99%),特异度为31%(95%CI 23%-40%)。
  • 检测PDR使用7视野ETDRS图像的敏感度为85%(95%CI 77%-91%)、特异度为48%(95%CI 41%-56%)。
  • 检测PDR使用UWF图像的敏感度为83%(95%CI 75%-89%)、特异度为54%(95%CI 46%-61%)。
  • 检测高危PDR使用UWF图像的敏感度为87%(95%CI 78%-93%)、特异度为49%(95%CI 42%-56%),使用7视野ETDRS图像的敏感度为80%(95%CI 69%-88%)、特异度为40%(95%CI 34%-47%)。
  • 与标准照护相比,新路径每100次DME随访可节省1390英镑,每100次PDR随访可节省461至1189英镑。

关键数值与推荐

  • 主要结局为新路径的敏感度。
  • 次要结局包括特异度、路径间一致性、成本、可接受性、需后续眼科医师评估的比例、无法成像的比例以及图像不合格或结果不确定的比例。

临床怎么用

  • 新路径可作为释放眼科医师资源的策略,用于检测既往治疗过的DME或PDR复发。
  • 实施时应参考使用者建议,保留定期眼科医师评估并考虑即时反馈机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The increasing diabetes prevalence and advent of new treatments for its major visual-threatening complications (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]), which require frequent life-long follow-up, have increased hospital demands markedly. Subsequent delays in patient's evaluation and treatment are causing sight loss. Strategies to increase capacity are needed urgently. The retinopathy (EMERALD) study tested diagnostic accuracy, acceptability, and costs of a new health care pathway for people with previously treated DME or PDR. DESIGN: Prospective, multicenter, case-referent, cross-sectional, diagnostic accuracy study undertaken in 13 hospitals in the United Kingdom. PARTICIPANTS: Adults with type 1 or 2 diabetes previously successfully treated DME or PDR who, at the time of enrollment, had active or inactive disease. METHODS: A new health care pathway entailing multimodal imaging (spectral-domain OCT for DME, and 7-field Early Treatment Diabetic Retinopathy Study [ETDRS] and ultra-widefield [UWF] fundus images for PDR) interpreted by trained nonmedical staff (ophthalmic graders) to detect reactivation of disease was compared with the current standard care (face-to-face examination by ophthalmologists). MAIN OUTCOME MEASURES: Primary outcome: sensitivity of the new pathway. SECONDARY OUTCOMES: specificity; agreement between pathways; costs; acceptability; proportions requiring subsequent ophthalmologist assessment, unable to undergo imaging, and with inadequate images or indeterminate findings. RESULTS: The new pathway showed sensitivity of 97% (95% confidence interval [CI], 92%-99%) and specificity of 31% (95% CI, 23%-40%) to detect DME. For PDR, sensitivity and specificity using 7-field ETDRS images (85% [95% CI, 77%-91%] and 48% [95% CI, 41%-56%], respectively) or UWF images (83% [95% CI, 75%-89%] and 54% [95% CI, 46%-61%], respectively) were comparable. For detection of high-risk PDR, sensitivity and specificity were higher when using UWF images (87% [95% CI, 78%-93%] and 49% [95% CI, 42%-56%], respectively, for UWF versus 80% [95% CI, 69-88%] and 40% [95% CI, 34%-47%], respectively, for 7-field ETDRS images). Participants preferred ophthalmologists' assessments; in their absence, they preferred immediate feedback by graders, maintaining periodic ophthalmologist evaluations. When compared with the current standard of care, the new pathway could save £1390 per 100 DME visits and between £461 and £1189 per 100 PDR visits. CONCLUSIONS: The new pathway has acceptable sensitivity and would release resources. Users' suggestions should guide implementation.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Lois N, Cook JA, Wang A, et al. Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study. Ophthalmology. 2020. PMID: 33130144. doi:10.1016/j.ophtha.2020.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。